Jian Carrot-Zhang

Assistant Attending, Computational Oncologist
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Jian Carrot-Zhang

Assistant Attending, Computational Oncologist
Share
Share
Jian Carrot-Zhang

Office Phone

646-608-7645

Email

[email protected]

URL

View Jian Carrot-Zhang's Lab

Dr. Jian Carrot-Zhang, PhD, is a new Assistant Member in the Computational Oncology Service. Her research focuses on understanding germline-somatic interactions in multi-ethnic populations. She develops computational and statistical approaches to characterize ancestral effects on the cancer genomes. Dr. Carrot-Zhang holds a joint appointment in the Clinical Genetics Service of the Department of Medicine to bridge the gap between germline genetics and somatic genomics. She has also led multiple research projects in collaboration with The Cancer Genome Atlas (TCGA) research network. Dr. Carrot-Zhang obtained her PhD in Human Genetics from McGill University and has trained at Dana-Farber Cancer Institute as a postdoctoral research fellow with Dr. Matthew Meyerson. Prior to MSKCC, she was an Instructor in Medicine in Harvard Medical School. Dr. Carrot-Zhang authored many publications in high-ranking journals and holds several awards including a K99 Award from NCI and a Banting Fellowship from CIHR.

Publications

Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers. Jiagge E, Jin DX, Newberg JY, Perea-Chamblee T, Pekala KR, Fong C, Waters M, Ma D, Dei-Adomakoh Y, Erb G, Arora KS, Maund SL, Njiraini N, Ntekim A, Kim S, Bai X, Thomas M, van Eeden R, Hegde P, Jee J, Chakravarty D, Schultz N, Berger MF, Frampton GM, Sokol ES, Carrot-Zhang J. Cancer Cell. 2023 Nov 13;41(11):1963-1971.e3. Epub 2023 Oct 26. PMID: 37890492.

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, Xu W, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, Choueiri TK, Schrag D, Carrot-Zhang J*, Gusev A*. Cancer Cell. 2022 Oct 10;40(10):1161-1172.e5. Epub 2022 Sep 29. PMID: 36179682; PMCID: PMC9559771.

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, Mitsuishi Y, Ha G, Campbell JD, Oxnard GR, Arrieta O, Cardona AF, Gusev A, Meyerson M. Cancer Discov. 2021 Mar;11(3):591-598. Epub 2020 Dec 2. PMID: 33268447; PMCID: PMC7933062.

Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, Frampton GM, Han S, Hoadley KA, Kemal A, Laird PW, Lazar AJ, Le X, Oak N, Shen H, Wong CK, Zenklusen JC, Ziv E; Cancer Genome Atlas Analysis Network; Cherniack AD, Beroukhim R. Cancer Cell. 2020 May 11;37(5):639-654.e6.PMID: 32396860; PMCID: PMC7328015.

Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, Gilpin C, Castellsagué E, Silva-Smith R, Plourde F, Wu M, Saskin A, Arseneault M, Karabakhtsian RG, Reilly EA, Ueland FR, Margiolaki A, Pavlakis K, Castellino SM, Lamovec J, Mackay HJ, Roth LM, Ulbright TM, Bender TA, Georgoulias V, Longy M, Berchuck A, Tischkowitz M, Nagel I, Siebert R, Stewart CJ, Arseneau J, McCluggage WG, Clarke BA, Riazalhosseini Y, Hasselblatt M, Majewski J, Foulkes WD.Nat Genet. 2014 May;46(5):438-43. Epub 2014 Mar 23. PMID: 24658002.

*co-senior

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Jian Carrot-Zhang discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures